Pepticom is a leader in AI-driven peptide-based therapeutics, focusing on the development of innovative treatments for autoimmune diseases. The company is advancing its oral IL-17 inhibitor program, which includes the design of synthetic, small cyclic peptidomimetic inhibitors targeting IL-17A and IL-17F isoforms. These compounds, composed of non-natural amino acids, offer enhanced stability and extended half-life, marking significant progress in next-generation drug discovery.